Merck licenses seven manufacturers to produce alimatravir, targeting high-burden regions
Category: Business
Aspen Pharmacare and Universal Corporation Limited (UCL) have emerged as key players in the global fight against HIV, following Merck's announcement on July 26, 2026, that both companies are among seven manufacturers licensed to produce alimatravir, an experimental once-monthly HIV prevention pill. This initiative aims to provide access to the medication in 129 low- and middle-income countries, including all African nations.
The licensing agreements are a strategic move by Merck, intended to expedite the availability of the drug, which is currently undergoing late-stage clinical trials. By issuing these voluntary licenses before the completion of the trials, Merck hopes to mitigate delays in the supply chain if the drug receives regulatory approval. The company’s proactive approach stands in stark relief to Gilead’s strategy concerning lenacapavir, which has faced criticism for not including any Sub-Saharan African manufacturers in its licensing agreements.
According to Aspen’s head of strategic trade, Stavros Nicolaou, the pill is a game-changer in HIV prevention. “It’s one tablet, once a month. It takes one hour to work, and you have one week’s forgiveness,” he explained. Nicolaou believes that alimatravir could be a superior alternative to lenacapavir, which is administered as a twice-yearly injection. He added that the oral format may facilitate broader distribution, as it does not necessitate healthcare worker administration.
In addition to Aspen and UCL, the other manufacturers licensed by Merck include Quality Chemical Industries from Uganda and four companies based in India: Aurobindo, Cipla, Emcure, and Viatris. This diverse group of manufacturers reflects a commitment to improving healthcare security across the continent and reducing reliance on imported medicines.
Alimatravir, also known as MK-8527, is categorized as a pre-exposure prophylaxis (PrEP) pill, aimed at preventing HIV infection among individuals who are HIV-negative but at high risk of exposure. The drug operates as a nucleoside reverse transcriptase translocation inhibitor (NRTTI), disrupting the formation of viral DNA, which is a key step in the replication process of HIV.
Merck's decision to license these manufacturers before the completion of clinical trials is seen as a means to prepare for immediate production upon regulatory approval. Paul Schaper, head of global pharmaceutical public policy at Merck, noted, “We’re likely not to have any trial results until the second half of next year, but this will give time for the generic licensees to start working to scale up their production.”
This initiative comes at a time when sub-Saharan Africa continues to bear a disproportionate burden of the global HIV epidemic, with over 40.9 million people living with HIV worldwide as of 2025. The World Health Organization has consistently urged governments and pharmaceutical companies to improve access to affordable HIV medicines through measures such as voluntary licensing and increased competition among generic manufacturers.
The significance of this licensing agreement matters. Historically, sub-Saharan African manufacturers have been excluded from early licensing opportunities for new HIV medications, which has hindered local production capabilities and access to life-saving treatments. Merck’s move to include these manufacturers from the outset marks a notable shift in the industry’s approach to addressing the HIV crisis in the region.
Health activists have expressed concern that Merck's licensing strategy excludes several Latin American countries, including Brazil, Peru, Argentina, and Colombia, where participants in the phase 3 clinical trials are located. These activists argue that the ethical principle of benefiting participants in scientific research is being violated. Asia Russell, executive director of Health GAP, called on Merck to commit to a public price of $4.50 per year for the drug and to supply at least six million people during the initial phase of production.
As the clinical trials for alimatravir progress, two specific studies are underway: EXPrESSIVE-10, which focuses on adolescent girls and young women in South Africa, Kenya, and Uganda; and EXPrESSIVE-11, which evaluates the pill among men who have sex with men, transgender individuals, and nonbinary people across 16 countries. The results of these trials are expected in the first quarter of 2027, which will be a defining moment for the future of this innovative HIV prevention strategy.
If successful, alimatravir could revolutionize HIV prevention by becoming the world’s first monthly oral treatment, offering a more convenient alternative to the daily regimen required by current PrEP medications. This could significantly improve adherence among populations that struggle with daily pill schedules, such as young women and other high-risk groups.
In addition to improving access to HIV prevention, local production of alimatravir is anticipated to strengthen healthcare security across Africa. By reducing reliance on imported medicines, countries can bolster their capacity to respond to health crises more effectively. The anticipated approval of alimatravir could lead to a broader shift toward long-acting prevention options, which are increasingly viewed as necessary for combating the HIV epidemic.
The next steps for Merck and its licensed manufacturers will involve ramping up production capabilities in anticipation of regulatory approval. As the world watches the developments in the clinical trials, the potential impact of alimatravir on global HIV prevention efforts remains a focal point in the fight against the epidemic.
With the stakes so high, the upcoming months will be critically important. The results of the phase 3 trials are set to be released in early 2027, and the healthcare community will be closely monitoring the outcomes, which may shape the future of HIV prevention strategies.